Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 16, 2024
Reporting Period: Event date February 16, 2024; Compliance achieved February 15, 2024.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
Regulatory Status Change: The Company regained compliance with the Nasdaq Listing Rule 5450(a)(1) (Bid Price Rule).
Previous Status: On December 6, 2023, the Company received notice of non-compliance because its common stock failed to maintain a minimum bid price of $1.00 per share.
Resolution: The Company successfully maintained a closing bid price of $1.00 per share or more for 10 consecutive business days, with the requirement met on February 15, 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the receipt of a letter from the Nasdaq Listing Qualifications Department notifying the Company of regained compliance.
Risks and Contingencies: The filing addresses the risk of delisting due to low stock price, which has been temporarily resolved. No new risks, guidance, or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of Karyopharm Therapeutics Inc. (KPTI) to ensure it remains above the $1.00 minimum bid price threshold.
- Review the Company's previous Form 8-K filed on December 12, 2023, for details on the initial non-compliance notice.
- Monitor future Nasdaq communications for any potential recurrence of bid price non-compliance.